Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. - Wikidata - awgldk - TriplyDB

Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors.

Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors.

http://www.wikidata.org/entity/Q35103872

about

Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature Insights into bombesin receptors and ligands: Highlighting recent advances In vitro and in vivo evaluation of a (18)F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging A high-affinity, high-stability photoacoustic agent for imaging gastrin-releasing peptide receptor in prostate cancer.Critical design issues in the targeted molecular imaging of cell surface receptors.Intracellular degradation of somatostatin-14 following somatostatin-receptor3-mediated endocytosis in rat insulinoma cells.Peptide-mediated cellular uptake of cryptophane.Peptide-based probes for targeted molecular imaging.A modeling analysis of the effects of molecular size and binding affinity on tumor targeting.Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease An overview of translational (radio)pharmaceutical research related to certain oncological and non-oncological applications.A review on various targeted anticancer therapies.Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analog Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas.Bombesin receptor-mediated imaging and cytotoxicity: review and current status F-Labeled GRPR Agonists and Antagonists: A Comparative Study in Prostate Cancer Imaging.In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer.Novel dimeric DOTA-coupled peptidic Y1-receptor antagonists for targeting of neuropeptide Y receptor-expressing cancers.Evaluation of copper-64-labeled somatostatin agonists and antagonist in SSTr2-transfected cell lines that are positive and negative for p53: implications for cancer therapy.In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer.Rapid kit-based (68)Ga-labelling and PET imaging with THP-Tyr(3)-octreotate: a preliminary comparison with DOTA-Tyr(3)-octreotate Radioiodinated Exendin-4 Is Superior to the Radiometal-Labelled Glucagon-Like Peptide-1 Receptor Probes Overcoming Their High Kidney Uptake.Cancer treatment using peptides: current therapies and future prospects Small Molecule Sequential Dual-Targeting Theragnostic Strategy (SMSDTTS): from Preclinical Experiments towards Possible Clinical Anticancer Applications.Peptide receptor targeting in cancer: the somatostatin paradigm.Tumor Targeting and Pharmacokinetics of a Near-Infrared Fluorescent-Labeled δ-Opioid Receptor Antagonist Agent, Dmt-Tic-Cy5.Design, synthesis, and biological evaluation of an antagonist-bombesin analogue as targeting vector.Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors.Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET).Novel, potent, and radio-iodinatable somatostatin receptor 1 (sst1) selective analogues Illuminating somatostatin analog action at neuroendocrine tumor receptors Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research.Preparation and biological evaluation of 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumors.Receptor-mediated tumor targeting with radiopeptides. Part 1. General principles and methods.Acetazolamide Serves as Selective Delivery Vehicle for Dipeptide-Linked Drugs to Renal Cell Carcinoma Peptide receptor therapies in neuroendocrine tumors.Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology.Peptide-based imaging agents for cancer detection.Receptor-mediated tumor targeting based on peptide hormones.

P2860

Q26849241-3815D8AE-A2DC-4FD2-8E08-8AA779F1A2E6 Q26992201-7F6971FF-029B-4B36-B5F6-20BCF0675E70 Q28081153-B3F367EB-3C8F-4A3B-91F6-BBE6490CBE12 Q28535729-5E23042C-DA80-4E74-B901-E19B299EE14E Q30406797-3DD0D360-229C-4BD9-8286-25A974AA70E4 Q30899036-E6FF496C-2355-44AB-BFE3-92A3780E89BB Q33360086-304CC58F-B037-4364-8CE2-6E04D80A6380 Q33377228-63A0E2FA-A6D4-495C-9393-DE056EF4DF46 Q33526620-0B9F92CD-1ED5-4C51-AB09-2A2ADB5417F2 Q33835328-1F320991-78CD-49DD-A7D2-1781B8A672DF Q33870879-2136D319-3867-4132-BC0C-D9335DC5C87C Q34093032-659AE773-7E59-4B4B-9408-88D4662245F3 Q34164735-5D1593A2-3619-43E5-B126-2AD73DC03FE1 Q34514544-0284DB88-48A4-4CC2-85AC-A81FA698E3B1 Q34579936-20BD956A-E519-4248-A413-6BCB81A02DD5 Q34684387-3C2E8A3D-408D-4E53-99B3-C8D8CB3F4D05 Q34912606-67056C4C-C6B7-4D4D-B110-2D9402DDAA76 Q34942281-F0D7CA5F-4CA6-4052-8212-C0B2534EE3BA Q35650466-1C8C5EC1-538D-4831-BE4F-7CC8162CC940 Q35713096-7C4CC213-753E-4650-B083-362A328B2449 Q35925945-4EE4E2F3-EB41-4C72-A2D5-4824566D5AEC Q36143456-89966707-230D-4E4D-A79C-5C02F4083EBF Q36253935-07998496-DD1F-4EF3-8E79-ED152D6B2F35 Q36515785-2CC329F3-DD15-42DB-9DFD-D957BE40FF9C Q36609881-DDF547A9-5D95-4E32-9C2F-EB311E9F7644 Q36638046-96A37F12-9373-4CFD-A4D2-32756152D027 Q37075319-8D8B5F99-E864-4000-9D88-E208043D7A69 Q37137779-4C366A8E-C4A1-4794-8278-CA24FB149EEC Q37152806-DBF6E9CE-590A-4BF9-ABF5-113A0F934A63 Q37356557-E3193EE2-F6E8-4EA4-BCDC-46EDB8811657 Q37426662-84965966-B5F7-4BD2-9749-A95E625116D5 Q37443562-1A63B895-B36E-4C8E-A86E-EE5ADCC9D0C4 Q37478003-7442CF39-D170-4353-88EE-47A077BCF51E Q37479595-198C5ED3-E560-4D3C-ADAE-E85A49CD8B17 Q37515337-083824D3-6574-411E-A812-0FDCB28A0932 Q37559487-2E902409-24AA-45A0-9F77-1F653E34397F Q37563878-A2AA3E1C-28C9-455C-964B-72C074352054 Q37579225-0565F956-93CB-486A-8645-CBF963668FDB Q37585965-9E8DDBB1-53E6-4937-A9B7-D1E7639F524A Q37641368-6DDAB0BA-C705-44C5-ACF7-C85CB1A4E8F7

P2860

Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors.

http://www.wikidata.org/entity/Q35103872

description

2006 nî lūn-bûn

@nan

2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Radiolabeled somatostatin rece ...... receptor targeting of tumors.

@ast

Radiolabeled somatostatin rece ...... receptor targeting of tumors.

@en

type

label

Radiolabeled somatostatin rece ...... receptor targeting of tumors.

@ast

Radiolabeled somatostatin rece ...... receptor targeting of tumors.

@en

prefLabel

Radiolabeled somatostatin rece ...... receptor targeting of tumors.

@ast

Radiolabeled somatostatin rece ...... receptor targeting of tumors.

@en

P1433

Q35103872-0D935F1D-85A2-4771-BAFB-9CD9245BC3EB

P1476

Q35103872-BB63AB65-55C8-48CD-B071-15DDF686167D

P2093

Q35103872-0E7142BC-5311-431C-8F5D-96AEA046D6F5

Q35103872-452B571E-ADE0-4BD8-B632-C7B4BF7BF8F3

Q35103872-502EA53E-6FC4-4628-BB82-AD87F65D6622

Q35103872-658EA3D0-12CE-4A25-8C9E-882E4525853E

Q35103872-6619F9E4-585F-4E9D-AA88-1B531F672086

Q35103872-6F434245-E663-4507-BDC9-135ED795D855

Q35103872-783675D9-A265-4E6B-AFB6-0798760FE3D7

Q35103872-87FEC6AE-E736-4026-98F4-3F489BD1288A

Q35103872-BD6FA24F-C2CB-4AF8-AAD1-056D7A8D5EC1

P2860

Q35103872-0092AEF7-A562-4141-99E1-74BB68548935

Q35103872-08B00524-6D27-4EF6-9151-732F7755954E

Q35103872-0D6BF013-3DA8-41CE-91AC-E165EEA7D7BB

Q35103872-1023F56B-45C3-4FE0-AD79-A9E2932B2385

Q35103872-1293F927-748F-4F78-805B-0A4ED386AFBD

Q35103872-2CDF402C-6665-4BE2-BC4D-14864B62D28D

Q35103872-3271F4F6-1084-488F-8AA4-9A0E53EE0CD6

Q35103872-369748BE-0C9B-4895-ABCE-CE7DFF7D11A0

Q35103872-439E2E95-9E00-454A-AE1D-EBC94A6570C6

Q35103872-5EEB682F-E2F3-43E5-8016-B24A47C0D4C9

P304

Q35103872-69881135-09EF-489E-AA0B-C2C2E3A0CD63

P31

Q35103872-E617A8A7-FBCF-4D01-8FFA-074C7C394E54

P356

Q35103872-3AD51F7F-BBEF-4354-93C8-A5F03B54508F

P407

Q35103872-4C642C7D-5486-410F-B4E7-DF10F9455A3B

P433

Q35103872-52D5F4AF-10BA-4514-9CA8-5C2A33E21AC0

P478

Q35103872-C89A23AD-B08C-404E-841D-415685B9A32B

P50

Q35103872-1044A588-C10B-40B0-AD9E-4E3B078203D3

P577

Q35103872-DDAF5A39-579C-41F0-AE1A-2D30A1006AFF

P5875

Q35103872-12E1D0A2-BFC9-4272-822E-55D01EEE8698

P698

Q35103872-2FA908BF-A555-4C73-86E1-2854EFC5D9D6

P932

Q35103872-4422989F-C705-495A-99B2-83FECA614F71

P356

PNAS.0607761103

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Radiolabeled somatostatin rece ...... receptor targeting of tumors.

@en

P2093

Beatrice Waser

http://www.w3.org/2001/XMLSchema#string

Damian Wild

http://www.w3.org/2001/XMLSchema#string

Hanwen Zhang

http://www.w3.org/2001/XMLSchema#string

Helmut R Mäcke

http://www.w3.org/2001/XMLSchema#string

Jean Rivier

http://www.w3.org/2001/XMLSchema#string

Judit Erchegyi

http://www.w3.org/2001/XMLSchema#string

Mihaela Ginj

http://www.w3.org/2001/XMLSchema#string

Renzo Cescato

http://www.w3.org/2001/XMLSchema#string

Xuejuan Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Somatostatin and its receptor family

Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists

Receptor targeting for tumor localisation and therapy with radiopeptides.

The pathophysiological consequences of somatostatin receptor internalization and resistance.

Peptide receptors as molecular targets for cancer diagnosis and therapy.

SST3-selective potent peptidic somatostatin receptor antagonists.

Opportunities in somatostatin research: biological, chemical and therapeutic aspects.

Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists.

Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters.

Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy.

P304

16436-16441

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0607761103

http://www.w3.org/2001/XMLSchema#string

P407

P433

44

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

Jean Claude Reubi

P577

2006-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6738741

http://www.w3.org/2001/XMLSchema#string

P698

17056720

http://www.w3.org/2001/XMLSchema#string

P932

1618814

http://www.w3.org/2001/XMLSchema#string